Active	Status	Sponsor type	Region	Phase	Filter
11 Active 11 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhu, Xiaodong
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC	Recruiting	3	500	Europe, Japan, US, RoW	JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy	Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA	Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged	06/26	06/27
FUSCC-HER2-G, NCT04960943: Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors	Recruiting	2	60	RoW	Pyrotinib with or without trastuzumab, pyrotinib with other drugs	Fudan University	Gastrointestinal Tumor, Effect of Drug	09/22	03/23
NCT05095636: Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer	Recruiting	2	102	RoW	Apatinib Mesylate, Camrelizumab	Fudan University	Gastric Cancer, Metastasis	03/23	09/23
NeoLeap-HCC, NCT05389527: Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma	Active, not recruiting	2	43	RoW	Pembrolizumab+Lenvatinib	Shanghai Zhongshan Hospital, Merck Sharp & Dohme LLC	Carcinoma, Hepatocellular	12/23	07/25
NCT05982834: Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC	Recruiting	1/2	43	RoW	Disitamab Vedotin combined with fruquintinib and Tislelizumab	Fudan University	HER2-positive Gastric Cancer, Immunotherapy	05/25	12/25
HRS-5632-101, NCT06732154: A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects	Not yet recruiting	1	50	RoW	HRS-5632, Placebo	Fujian Shengdi Pharmaceutical Co., Ltd.	Dyslipidemia	02/26	02/26
G/GEJ cancer, NCT06158919: A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer	Recruiting	N/A	58	RoW	Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine	Fudan University	Gastric Cancer/Adenocarcinoma of Esophagogastric Junction	11/24	11/26
TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor	Active, not recruiting	N/A	126	US, RoW	Felix NeuroAI Wristband, Sham Device	Fasikl Inc.	Essential Tremor	11/24	11/25
Sheng, Xiaoyang
NCT05585021: Clinical Study on the Effect of Probiotic Compound Powder on the Immunity Improvement of Preschool Children	Completed	N/A	140	RoW	Wonderlab Kids instant probiotics, Instant probiotic placebo	Shenzhen Precision Health Food Technology Co. Ltd.,	Immunity	04/23	04/23
NCT05695300: Gut Health,Feces Characteristics and Growth of Infants Fed With a New Infant Organic Formula	Active, not recruiting	N/A	75	RoW	BLM ORGANIC GOLD+, BLM ORGANIC, Breast milk	Bellamy's Organic Pty Ltd	Infant Development	05/23	05/23
NCT05670678: Improved Respiratory Infection by Consuming Lactoferrin Fortified a2 Growing up Formula in Children of 2 to 3 Year Old	Completed	N/A	200	RoW	a2 growing up stage 3 formula puls lactoferrin supplement, Enfinitas growing up stage 3 formula	a2 Milk Company Ltd., Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Respiratory Infection, Diarrheal Disease	05/23	05/23